Logo image of BCT.CA

BRIACELL THERAPEUTICS CORP (BCT.CA) Stock Fundamental Analysis

Canada - TSX:BCT - CA1079303071 - Common Stock

15.9 CAD
+1.92 (+13.73%)
Last: 11/7/2025, 7:00:00 PM
Fundamental Rating

2

BCT gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 22 industry peers in the Biotechnology industry. BCT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. BCT is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

BCT had negative earnings in the past year.
In the past year BCT has reported a negative cash flow from operations.
BCT had negative earnings in each of the past 5 years.
BCT had a negative operating cash flow in each of the past 5 years.
BCT.CA Yearly Net Income VS EBIT VS OCF VS FCFBCT.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

Looking at the Return On Assets, with a value of -123.71%, BCT is in line with its industry, outperforming 54.55% of the companies in the same industry.
Looking at the Return On Equity, with a value of -321.51%, BCT is in line with its industry, outperforming 59.09% of the companies in the same industry.
Industry RankSector Rank
ROA -123.71%
ROE -321.51%
ROIC N/A
ROA(3y)-73.12%
ROA(5y)-202.73%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BCT.CA Yearly ROA, ROE, ROICBCT.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K -1K 1.5K

1.3 Margins

BCT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BCT.CA Yearly Profit, Operating, Gross MarginsBCT.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

BCT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BCT.CA Yearly Shares OutstandingBCT.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50K 100K 150K 200K 250K
BCT.CA Yearly Total Debt VS Total AssetsBCT.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

BCT has an Altman-Z score of -19.39. This is a bad value and indicates that BCT is not financially healthy and even has some risk of bankruptcy.
BCT has a Altman-Z score (-19.39) which is comparable to the rest of the industry.
There is no outstanding debt for BCT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -19.39
ROIC/WACCN/A
WACCN/A
BCT.CA Yearly LT Debt VS Equity VS FCFBCT.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M -20M

2.3 Liquidity

BCT has a Current Ratio of 1.37. This is a normal value and indicates that BCT is financially healthy and should not expect problems in meeting its short term obligations.
BCT's Current ratio of 1.37 is in line compared to the rest of the industry. BCT outperforms 54.55% of its industry peers.
BCT has a Quick Ratio of 1.37. This is a normal value and indicates that BCT is financially healthy and should not expect problems in meeting its short term obligations.
BCT has a Quick ratio of 1.37. This is comparable to the rest of the industry: BCT outperforms 59.09% of its industry peers.
Industry RankSector Rank
Current Ratio 1.37
Quick Ratio 1.37
BCT.CA Yearly Current Assets VS Current LiabilitesBCT.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for BCT have decreased strongly by -14343.33% in the last year.
EPS 1Y (TTM)-14343.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-428.48%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

BCT is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.83% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y90.98%
EPS Next 2Y40.47%
EPS Next 3Y25.73%
EPS Next 5Y18.83%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BCT.CA Yearly Revenue VS EstimatesBCT.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2M 4M 6M 8M 10M
BCT.CA Yearly EPS VS EstimatesBCT.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 0 -50 -100 -150 -200

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BCT. In the last year negative earnings were reported.
Also next year BCT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BCT.CA Price Earnings VS Forward Price EarningsBCT.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BCT.CA Per share dataBCT.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -50 -100 -150

4.3 Compensation for Growth

A more expensive valuation may be justified as BCT's earnings are expected to grow with 25.73% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.47%
EPS Next 3Y25.73%

More info and screens

0

5. Dividend

5.1 Amount

BCT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BRIACELL THERAPEUTICS CORP

TSX:BCT (11/7/2025, 7:00:00 PM)

15.9

+1.92 (+13.73%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-15 2025-10-15/amc
Earnings (Next)12-15 2025-12-15
Inst Owners9.66%
Inst Owner ChangeN/A
Ins Owners3.94%
Ins Owner ChangeN/A
Market Cap29.89M
Revenue(TTM)N/A
Net Income(TTM)-11.58M
Analysts80
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-95.6%
Min EPS beat(2)-172.28%
Max EPS beat(2)-18.91%
EPS beat(4)2
Avg EPS beat(4)3.82%
Min EPS beat(4)-172.28%
Max EPS beat(4)119.8%
EPS beat(8)5
Avg EPS beat(8)17.93%
EPS beat(12)6
Avg EPS beat(12)-15.85%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-900%
EPS NQ rev (3m)-900%
EPS NY rev (1m)0%
EPS NY rev (3m)43.55%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 5.88
P/tB 6.21
EV/EBITDA N/A
EPS(TTM)-180.86
EYN/A
EPS(NY)-16.32
Fwd EYN/A
FCF(TTM)-16.76
FCFYN/A
OCF(TTM)-16.42
OCFYN/A
SpS0
BVpS2.7
TBVpS2.56
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -123.71%
ROE -321.51%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-73.12%
ROA(5y)-202.73%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.37
Quick Ratio 1.37
Altman-Z -19.39
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-14343.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-428.48%
EPS Next Y90.98%
EPS Next 2Y40.47%
EPS Next 3Y25.73%
EPS Next 5Y18.83%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y13.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-42.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-39.83%
OCF growth 3YN/A
OCF growth 5YN/A

BRIACELL THERAPEUTICS CORP / BCT.CA FAQ

What is the fundamental rating for BCT stock?

ChartMill assigns a fundamental rating of 2 / 10 to BCT.CA.


What is the valuation status for BCT stock?

ChartMill assigns a valuation rating of 1 / 10 to BRIACELL THERAPEUTICS CORP (BCT.CA). This can be considered as Overvalued.


What is the profitability of BCT stock?

BRIACELL THERAPEUTICS CORP (BCT.CA) has a profitability rating of 1 / 10.


What is the earnings growth outlook for BRIACELL THERAPEUTICS CORP?

The Earnings per Share (EPS) of BRIACELL THERAPEUTICS CORP (BCT.CA) is expected to grow by 90.98% in the next year.